Melancholic features in major depression - a European multicenter study.
Adult
Antidepressive Agents
/ therapeutic use
Antipsychotic Agents
/ therapeutic use
Benzodiazepines
/ therapeutic use
Clinical Trials as Topic
Depressive Disorder, Major
/ classification
Europe
Female
Humans
Inpatients
Male
Middle Aged
Outpatients
Prevalence
Selective Serotonin Reuptake Inhibitors
/ therapeutic use
Antidepressants
Augmentation/combination treatment
Major depressive disorder
Melancholia
Treatment response
Journal
Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617
Informations de publication
Date de publication:
30 08 2021
30 08 2021
Historique:
received:
21
09
2020
revised:
31
01
2021
accepted:
12
02
2021
pubmed:
21
2
2021
medline:
8
2
2022
entrez:
20
2
2021
Statut:
ppublish
Résumé
There is still a debate, if melancholic symptoms can be seen rather as a more severe subtype of major depressive disorder (MDD) or as a separate diagnostic entity. The present European multicenter study comprising altogether 1410 MDD in- and outpatients sought to investigate the influence of the presence of melancholic features in MDD patients. Analyses of covariance, chi-squared tests, and binary logistic regression analyses were accomplished to determine differences in socio-demographic and clinical variables between MDD patients with and without melancholia. We found a prevalence rate of 60.71% for melancholic features in MDD. Compared to non-melancholic MDD patients, they were characterized by a significantly higher likelihood for higher weight, unemployment, psychotic features, suicide risk, inpatient treatment, severe depressive symptoms, receiving add-on medication strategies in general, and adjunctive treatment with antidepressants, antipsychotics, benzodiazepine (BZD)/BZD-like drugs, low-potency antipsychotics, and pregabalin in particular. With regard to the antidepressant pharmacotherapy, we found a less frequent prescription of selective serotonin reuptake inhibitors (SSRIs) in melancholic MDD. No significant between-group differences were found for treatment response, non-response, and resistance. In summary, we explored primarily variables to be associated with melancholia which can be regarded as parameters for the presence of severe/difficult-to treat MDD conditions. Even if there is no evidence to realize any specific treatment strategy in melancholic MDD patients, their prescribed medication strategies were different from those for patients without melancholia.
Identifiants
pubmed: 33609603
pii: S0278-5846(21)00044-0
doi: 10.1016/j.pnpbp.2021.110285
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Antipsychotic Agents
0
Serotonin Uptake Inhibitors
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110285Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.